A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan or MabThera in patients with active rheumatoid arthritis, previously treated with Rituxan or MabThera

Trial Profile

A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan or MabThera in patients with active rheumatoid arthritis, previously treated with Rituxan or MabThera

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms ASSIST-RT
  • Sponsors HEXAL; Sandoz
  • Most Recent Events

    • 14 Nov 2017 Results from this trial were presented at the American College of Rheumatology (ACR) Annual Meeting according to a Sandoz media release.
    • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 29 Oct 2016 This trial was completed in Germany (end date: 2016-10-12), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top